Agents such as tyrosine kinase inhibitors and mTOR inhibitors have been investigated; however, their efficacy has been limited in clinical settings, often due to the complex and heterogeneous nature of glioblastoma, as well as the blood–brain barrier, which restricts drug delivery [36,37]. Here, MTOR is linked to glioblastoma.